Tasimelteon
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tasimelteon |
| DrugBank ID | DB09071 |
| Brand Names (EU) | Hetlioz |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.48% |
Approved Indication (EMA)
Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bilateral parasagittal parieto-occipital polymicrogyria | 99.48% | DL |
| 2 | insomnia (disease) | 99.47% | DL |
| 3 | amyotrophic lateral sclerosis | 99.36% | DL |
| 4 | endogenous depression | 99.36% | DL |
| 5 | axial spondylometaphyseal dysplasia | 99.23% | DL |
| 6 | monomelic amyotrophy | 99.22% | DL |
| 7 | amyotrophic lateral sclerosis, susceptibility to | 99.19% | DL |
| 8 | lower motor neuron syndrome with late-adult onset | 99.17% | DL |
| 9 | Mills syndrome | 99.15% | DL |
| 10 | amyotrohpic lateral sclerosis type 22 | 99.13% | DL |
| 11 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | 99.10% | DL |
| 12 | autosomal dominant mitochondrial myopathy with exercise intolerance | 99.06% | DL |
| 13 | lethal arthrogryposis-anterior horn cell disease syndrome | 99.05% | DL |
| 14 | anxiety disorder | 98.74% | DL |
| 15 | sleep disorder, initiating and maintaining sleep | 98.60% | DL |
| 16 | benign paroxysmal torticollis of infancy | 98.57% | DL |
| 17 | childhood apraxia of speech | 98.55% | DL |
| 18 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 98.40% | DL |
| 19 | rhabdoid tumor | 98.39% | DL |
| 20 | familial generalized lentiginosis | 98.36% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.